Company: GIFLF
Filing Date: 2025-06-05
Form Type: 6-K
Source: 0001104659-25-056816
Chunk: 11

Company: Grifols SA
Filing Date: 2025-06-05
Form: 6-K
Chunk 11
---
, Ipsen, Jazz Pharmaceuticals, Hikma, Richter Gedeon Lundbeck, Organon & Co, Bausch Health.

These companies were selected based
on their relevance to Grifols´ operation model and industry positioning an include members of the ISS P4P peer group, and other
companies chosen by Grifols as appropriate market comparators. ISS creates peer groups based on revenues and sector. Companies included
in Grifols' peer group is based on business similarities.

The special committee may update or
adjust the peer group if needed, to reflect changes in industry conditions or corporate structure, ensuring continued alignment with the
principles outlines herein.

8. Determination of level of achievement and payout:

For Participants who are members of
the senior management team, the Appointments and Remuneration Committee will monitor the objectives and the level of achievement will
be determined by the Board of Director's upon recommendation by the Appointments and Remuneration Committee.

For Participants who are not members
of the senior management team, the special committee led by the Company's Chief Executive Officer will monitor the objectives and determine
their level of achievement.

The Plan’s payment curve allows
for payouts ranging from 0% to 150% of the target award, depending on the level of achievement of the performance criteria.

The specific payout for Participants
who are members of the senior management team will be decided by the Board of Directors prior proposal of the Company's Appointments and
Remuneration Committee.

The specific payout for the Participants
who are not members of the senior management team will be decided by the special committee led by the Company's Chief Executive Officer.

<div align='center'>15</div>

9. Holding period and clawback:

The Plan includes:

| · | A holding period of one (1) year following delivery of vested shares, unless the Participant maintains                                   
 property, at the time of the intended transfer, of sufficient shares equivalent in value to an amount of at least twice his or her fixed 
 annual remuneration through the ownership of shares, options or other financial instruments.                                             |

| · | A clawback provision, requiring the return of awards or their cash equivalent in case of fraud, unethical 
 behavior or errors in the performance metrics that led to vesting.                                        |

| B. | To authorize the Board of Directors, with express powers of substitution, to implement, develop, formalize,                            
 execute and, where appropriate, modify the Plan, adopting any resolutions and signing any documents that